Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07167446 · ClinicalTrials.gov registry record · Early Phase 1
Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy
A Early Phase 1 study of Peripheral Neuropathy Due to Chemotherapy and Metastatic Colorectal Cancer (CRC), sponsored by Fox Chase Cancer Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07167446: Recruiting Early Phase 1 study of Peripheral Neuropathy Due to Chemotherapy and Metastatic Colorectal Cancer (CRC), sponsored by Fox Chase Cancer Center.
NCT07167446 is a Early Phase 1 study of Peripheral Neuropathy Due to Chemotherapy and Metastatic Colorectal Cancer (CRC) that is actively recruiting participants, run by Fox Chase Cancer Center. The registered enrollment target is 30 participants, below the 56-participant average among 6 other Peripheral Neuropathy Due to Chemotherapy trials with a reported enrollment target (46% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07167446, a Early Phase 1 study of Peripheral Neuropathy Due to Chemotherapy and Metastatic Colorectal Cancer (CRC), is actively recruiting participants, sponsored by Fox Chase Cancer Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot, prospective, randomized study evaluating the feasibility and acceptability of incorporating hemp-derived cannabidiol (CBD) supplementation to prevent oxaliplatin-induced peripheral neuropathy (OIPN) in patients receiving oxaliplatin-based chemotherapy for colorectal cancer (CRC). Participants will be randomized to receive either CBD capsules in addition to standard therapy or standard therapy alone.
Conditions Studied
Interventions
- DRUG Cannabidiol (CBD)
- DRUG oxaliplatin-based chemotherapy
Study Locations (1)
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-10-14 |
| Est. Completion | 2028-09-07 |
| Phase | Early Phase 1 |
What NCT07167446 shows while recruiting
NCT07167446 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 56-participant average among 6 other Peripheral Neuropathy Due to Chemotherapy trials with a reported enrollment target (46% lower).
The record links to 3 conditions, with Peripheral Neuropathy Due to Chemotherapy appearing as the primary indexed condition, and to 2 interventions - of which Cannabidiol (CBD) is the first listed.
NCT07167446 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07167446 about?
NCT07167446 is a clinical study titled "Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy". This is a pilot, prospective, randomized study evaluating the feasibility and acceptability of incorporating hemp-derived cannabidiol (CBD) supplementation to prevent oxaliplatin-induced peripheral neuropathy (OIPN) in patients receiving oxaliplatin-based chemotherapy for colorectal cancer (CRC). Pa...
What is the current status of trial NCT07167446?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2025-10-14. Estimated completion is 2028-09-07.
What conditions does trial NCT07167446 study?
This clinical trial studies the following conditions: Peripheral Neuropathy Due to Chemotherapy, Metastatic Colorectal Cancer (CRC), Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients.
What interventions are being tested in trial NCT07167446?
The interventions under investigation include: Cannabidiol (CBD) (DRUG), oxaliplatin-based chemotherapy (DRUG).
Who is sponsoring clinical trial NCT07167446?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07167446 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Neuropathy Due to Chemotherapy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study
RECRUITING · Early Phase 1
-
Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems
RECRUITING · NA
-
Feasibility Testing of a Tai Chi Program for Chemotherapy-Induced Peripheral Neuropathy Treatment (TCT)
RECRUITING · NA
-
Patient-identified Values as Outcome Targets (PIVOT) Feasibility Pilot Trial
RECRUITING · NA
-
Fall Risk and Quality of Life: in Individuals With Cancer Treatment Related Peripheral Neuropathy.
RECRUITING
-
Closed Loop Spinal Cord Stimulation for Chemotherapy Induced Peripheral Neuropathy, a Pilot Study.
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI